A5078598204- Cancer Treatment and Pharmacology
- Multiple Myeloma Research and Treatments
- Histone Deacetylase Inhibitors Research
- Lymphoma Diagnosis and Treatment
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
- Protein Degradation and Inhibitors
- Angiogenesis and VEGF in Cancer
- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Neutropenia and Cancer Infections
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Chemotherapy-induced organ toxicity mitigation
- Cancer therapeutics and mechanisms
- Viral-associated cancers and disorders
- Chemotherapy-related skin toxicity
- Chemotherapy-induced cardiotoxicity and mitigation
- Chronic Lymphocytic Leukemia Research
- Trace Elements in Health
- Wnt/β-catenin signaling in development and cancer
- Peroxisome Proliferator-Activated Receptors
Fujifilm (United States)
2023-2025
Acetylon Pharmaceuticals (United States)
2012-2017
AstraZeneca (Brazil)
2005-2008
Sarah Cannon
2007
Roche (United States)
2007
AstraZeneca (United States)
2004-2006
AstraZeneca (United Kingdom)
2001-2006
University Medical Center Utrecht
2006
Dana-Farber Cancer Institute
1992-2004
University of North Carolina at Greensboro
2003
The study was designed to determine the duration of complete response (CR) for patients with unresectable or metastatic breast cancer treated high-dose cyclophosphamide, thiotepa, and carboplatin (CTCb) while responding conventional-dose therapy.Eligibility criteria included histologically documented cancer, at least a partial (PR) therapy, no prior pelvic radiotherapy, cumulative doxorubicin less than 500 mg/m3, physiologic age between 18 55 years. Patients inadequate renal, hepatic,...
Purpose: Histone deacetylase (HDAC) inhibition improves the efficacy of proteasome for multiple myeloma but adds substantial toxicity. Preclinical models suggest that observed synergy is due to role HDAC6 in mediating resistance via aggresome/autophagy pathway protein degradation.Experimental Design: We conducted a phase I/II trial HDAC6-selective inhibitor ricolinostat define safety, preliminary efficacy, and recommended II dose combination with standard therapy. Patients relapsed or...
Abstract Purpose: To determine the efficacy and safety of ZD6474, an orally available inhibitor vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase with additional activity against epidermal receptor (EGFR) kinase, in patients previously treated metastatic breast cancer. Patients Methods: Eligible had histologically confirmed cancer received prior treatment anthracycline taxane; measurable disease was required. were enrolled sequentially into one two dose cohorts, 100 or...
Cyclophosphamide, which forms the nucleus for virtually all preparative regimens autologous bone marrow transplantation (ABMT), is an alkylating agent of cytotoxicity not directly caused by parent compound but its biologically active metabolites. Its nonmyelosuppressive toxicity in ABMT setting cardiomyopathy. We attempted to determine any correlation between plasma levels total cyclophosphamide and subsequent development cardiac dysfunction.Analyses derivation concentration-time curves...
Abstract Purpose: ZD6126 is a novel vascular targeting agent currently undergoing clinical evaluation. It acts by destabilizing the microtubulin of fragile and proliferating neoendothelial cells in tumors. The drug leads to blood vessel congestion, selective destruction vasculature, extensive necrosis experimental aim study reported here was assess ability dynamic contrast enhanced magnetic resonance imaging (MRI) measure antivascular effects Experimental Design: work carried out mice...
Cyclophosphamide, carmustine (BCNU), and etoposide (VP-16) (CBV) is a widely used conditioning regimen in autologous bone marrow transplantation (ABMT) of patients with refractory relapsed lymphoma. However, the maximum-tolerated dose (MTD) these agents when combination has not been systematically explored. We treated 58 (28 non-Hodgkin's lymphoma [NHL], 30 Hodgkin's disease [HD]) at seven levels CBV. Doses were cyclophosphamide 4,500 to 7,200 mg/m2, BCNU 450 600 g/m2, VP-16 1,200 2,000...
A retrospective study was performed to define clinical characteristics and therapeutic outcome for patients with large-cell immunoblastic lymphoma of the mediastinum.Fifty-seven who presented primary, mediastinal were retrospectively studied determine initial sites disease, radiologic characteristics, treatment, outcome, factors that have prognostic significance progression-free overall survival.Fifty-six 57 had disease confined above diaphragm. Bulky extensive intrathoracic infiltration...
PURPOSE Twenty-seven percent of responding metastatic breast cancer patients remain progression-free a median 29 months following one intensification course cyclophosphamide (6,000 mg/m2), thiotepa (500 and carboplatin (800 mg/m2) (CTCb) with autologous bone marrow transplantation (ABMT). European investigators report high complete response (CR) rates melphalan for cancer. This trial studied the feasibility two tandem high-dose therapies in an attempt to optimize disease duration. PATIENTS...
Bone marrow transplant patients have impaired responses to pure polysaccharide (PS) vaccines and are at an increased risk for disease caused by PS encapsulated pathogens such as Haemophilus influenzae type B (HIB) Streptococcus pneumoniae. We immunized 35 BMT (21 allogeneic 14 autologous) ages 2–45 years with pneumococcal (Pnu-imune 23), HIB-conjugate (HibTITER), tetanus toxoid vaccines. Patients were assigned receive either 12 24 months after transplantation or only. Only 19% of all...
ZD6126 is a novel vascular-targeting agent that induces selective effects on the morphology of endothelial cells by disrupting tubulin cytoskeleton. This leads to cell detachment and tumor vessel congestion, resulting in extensive central necrosis range xenograft models. Results from phase I dose-escalation study are reported.Thirty-two patients with advanced cancer received weekly infusion (5 28 mg/m2). Assessments for safety pharmacokinetics were performed. Circulating (CECs) quantified as...
PURPOSE Despite improvement in chemotherapy and supportive care over the past two decades, overall survival for patients with acute myelogenous leukemia (AML) remains poor; only 25% to 30% of individuals this disorder will be cured. In 1987, we initiated a prospective multiinstitution study designed improve long-term adults AML. METHODS We modified usual 7-day treatment scheme daunorubicin cytarabine high-dose (HiDAC) on days 8 through 10 (3 + 7 3). Allogeneic or autologous bone marrow...
Reeler (rl/rl) and reeler/wild-type (+/rl) mice synthesize Reln at subnormal rates, as do patients with schizophrenia, bipolar disorder, autism, thereby forming the basis for a hypothesis vulnerability to these psychopathologies justifying attention behavioral phenotypes of Reln-deficient mice. Tests gait, emotionality, social aggression, spatial working memory, novel-object detection, fear conditioning, sensorimotor reflex modulation revealed phenotype rl/rl, but not +/rl, be different from...
Abstract Purpose: Primary central nervous system (CNS) tumors represent a diverse group of tumor types with heterogeneous molecular mechanisms that underlie their formation and maintenance. CNS depend on angiogenesis often display increased activity ErbB-associated pathways. Current nonspecific therapies frequently have poor efficacy in many these types, so there is pressing need for the development novel targeted therapies. Experimental Design: ZD6474 novel, orally available low weight...
Abstract Background Yttrium‐90 FF‐21101 ( 90 Y–FF‐21101) is a radiopharmaceutical that targets P‐cadherin as therapy against solid tumors. A previously reported, first‐in‐human study determined dose of 25 mCi/m 2 was safe, and patient with clear cell carcinoma the ovary achieved complete response. In this article, authors report results Y–FF‐21101 treatment in an ovarian expansion cohort patients selected tumors who had known high expression. Methods The trial conducted open‐label...
PURPOSE A study was undertaken to improve our understanding of the clinicopathologic features and therapeutic outcome for adults with primary Ki-1 anaplastic large-cell lymphoma (ALCL). PATIENTS AND METHODS retrospective review records 31 adult patients ALCL performed. The analysis included stage distribution disease, tumor-cell phenotype, response initial salvage therapy, disease-free overall survival. RESULTS median age 44 years (range, 16 86). Forty-eight percent tested had lymphomas...
Retrospective review of 291 solid tumor and lymphoma patients undergoing autologous bone marrow transplantation (BMT) was performed to determine the influence pretransplant characteristics preparative regimen development hepatic venoocclusive disease (VOD). Twelve (4.1%) developed a clinical syndrome right upper quadrant (RUQ) tenderness or hepatomegaly, jaundice, ascites, with without encephalopathy, within 40 days reinfusion. Evidence metastatic liver only characteristic predictive for VOD...
PURPOSE We examined a consecutive series of 78 patients with non-Hodgkin's lymphoma treated on prospective protocols high-dose cyclophosphamide, carmustine (BCNU), and etoposide (CBV) plus autotransplantation to determine prognostic factors for time treatment failure. PATIENTS AND METHODS Patients relapsed, refractory, or poor-risk intermediate- high-grade were CBV autologous marrow peripheral-blood progenitor cell support. Patient characteristics before transplantation in univariate...
PURPOSE Women with locally unresectable and inflammatory breast carcinoma (IBC) have an approximately 30% 5-year disease-free survival (DFS) rate conventional multimodality therapy. A short but dose-intensive phase II trial was designed in attempt to improve outcome stage IIIB disease. Mastectomy performed after high-dose therapy evaluate pathologic response treatment. METHODS newly diagnosed disease received four 2-week cycles of doxorubicin 90 mg/m2 granulocyte colony-stimulating factor...